TABLE II— 28 NOCS RECEIVED FROM 12/01/14 TO 12/31/14

Case no.	Received date	Commencement notice end date	Chemical
P–14–0823	12/8/2014	12/6/2014	(G) Formaldehyde, polymer with substituted carbomonocycle, alkyl ether.
P–14–0820	12/8/2014	12/7/2014	(G) Formaldehyde, polymer with substituted carbomonocycles, alkyl ether.
P–14–0740	12/8/2014	12/8/2014	(S) D-Glucopyranose, oligomeric, c10-16-alkyl glycosides, polymers with 1,3-dichloro-2-propanol*.
P–14–0741	12/9/2014	11/16/2014	(S) Siloxanes and silicones, di-me, me3-[2-[(1-oxo-2-propen-1-yl)oxy]ethoxy]propyl, [[Dimethyl[3-[2-[(1-oxo-2-propen-1-yl)Oxy]ethoxy]Propyl]silyl]oxy]-terminated, polymers with chlorotrimethylsilane-iso-pr alc.-sodium silicate reaction products*.
P–13–0317	12/9/2014	12/2/2014	(G) Polyetherester.
P–13–0908	12/9/2014	12/2/2014	(G) Polyether polyester Urethane Phosphate.
P–14–0760	12/9/2014	12/4/2014	(G) Styrene-methacrylate copolymer.
P–11–0549	12/9/2014	12/9/2014	(S) 2-Butene, 1,1,1,4,4,4-hexafluoro-, (2z)-*.
P–14–0667	12/10/2014	11/18/2014	(G) Aromatic carboxylic acid.
P–14–0729	12/10/2014	11/21/2014	(G) Carboxylated nitrile rubber.
P–14–0668	12/10/2014	11/26/2014	(G) Aromatic carboxylic acid salt.
P–14–0543	12/10/2014	12/3/2014	(S) Benzoic acid, 2-([1,1′-biphenyl]-4-ylcarbonyl)-*.
P–14–0664	12/11/2014	11/19/2014	(G) 2-Propenoic acid, telomer with alkanediol mono-2-propenoate and sodium phosphinate (1:1), ammonium salt.
P–10–0364	12/11/2014	11/24/2014	(G) Bisphospite nickel cyanoalkyl complex.
P–14–0651	12/11/2014	12/8/2014	(G) Methylenediphenyl diisocyanate (MDI) prepolymer.
P–14–0582	12/12/2014	11/25/2014	(S) Siloxanes and silicones, di-me, bu group- and 3-(2-hydroxyethoxy)propyl group-terminated*.
P–14–0652	12/16/2014	11/19/2014	(G) Perfluoropolyether allyl ether.
P–14–0376	12/16/2014	11/26/2014	(G) Vegetable oil fatty acid, compds. With ethenyl heterocycle -2-ethylhexyl acrylate-2-hydroxyethyl methacrylate- polyalkylene ether methacrylate me ether.
P–14–0438	12/16/2014	12/4/2014	(G) Trialkyl substituted carboxylic acid, mixed esters with alkyl substituted carboxylic acid and polyol.
P–14–0752	12/16/2014	12/4/2014	(G) Acid salts, compounds With [(aminoalkyl)imino]bis[alcohol]-epoxy-cycloalkylamine-polymer-dialcoholamine reaction products.
P–14–0702	12/17/2014	11/21/2014	(G) Perfluoropolyether compound.
P–14–0287	12/17/2014	12/12/2014	(G) Butanedioic acid, mono(mixed hexadecen-1-yl and polyisobutylene) derivs., alkyl esters.
P–14–0633	12/18/2014	11/24/2014	(G) Fatty acids, tall-oil, reaction products.
P–14–0748	12/18/2014	11/24/2014	(G) Alkylpolyglycol ether phosphate ester.
P–14–0778	12/19/2014	12/18/2014	(G) Polyethylene glycol alkyl ethers.
P–14–0267	12/22/2014	11/7/2014	(S) Poly(oxy-1,2-ethanediyl), -[[(3-Isocyanatomethylphenyl)amino]carbonyl]—methoxy-*.
P–13–0866	12/22/2014	12/18/2014	(S) Oils, Aquilaria crassna*.
P–14–0058	12/29/2014	12/9/2014	(G) Alkylphosphinic acid.

If you are interested in information that is not included in these tables, you may contact EPA as described in Unit III. To access additional non-CBI information that may be available.

Authority: 15 U.S.C. 2601 *et seq.*

Dated: February 11, 2015.

Chandler Sirmons,

Acting Director, Information Management Division, Office of Pollution Prevention and Toxics.

[FR Doc. 2015–03460 Filed 2–19–15; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[ER–FRL–9019–6]

Environmental Impact Statements; Notice of Availability

Responsible Agency: Office of Federal Activities, General Information (202) 564–7146 or *http://www.epa.gov/compliance/nepa/*.

Weekly receipt of Environmental Impact Statements Filed 02/09/2015 Through 02/13/2015 Pursuant to 40 CFR 1506.9.

Notice

Section 309(a) of the Clean Air Act requires that EPA make public its comments on EISs issued by other Federal agencies. EPA's comment letters on EISs are available at: *http://www.epa.gov/compliance/nepa/eisdata.html.*

EIS No. 20150035, Final EIS, FHWA, TX, US 69/Loop 49 North Lindale Reliever Route, from IH 20 Southwest of Lindale to US 69 North of Lindale, Review Period Ends: 03/23/2015, Contact: Vernon Webb 903–510–9296.

EIS No. 20150036, Second Final Supplement, BOEM, AK, Chukchi Sea Planning Area, Oil and Gas Lease, Sale 193, Review Period Ends: 03/23/2015, Contact: Tim Holder 703–787–1744.

EIS No. 20150037, Draft EIS, USFS, OR, Granite Creek Watershed Mining Project, Comment Period Ends: 04/06/2015, Contact: Sophia Millar 541–263–1735.

EIS No. 20150038, Final EIS, USFS, ID, Crooked River Valley Rehabilitation Project, Review Period Ends: 04/13/2015, Contact: Jennie Fischer 208–983–4048.

EIS No. 20150039, Draft EIS, USACE, TX, Lower Bois D'Arc Creek Reservoir, Comment Period Ends: 04/21/2015, Contact: Andrew Commer 918–669–7400.

EIS No. 20150040, Final EIS, USFWS, ID, Deer Flat National Wildlife Refuge Comprehensive Conservation Plan, Review Period Ends: 03/23/2015, Contact: Annette de Knijf 208–467–9278.

Amended Notices

EIS No. 20150028, Final EIS, USFS, ID, Clear Creek Integrated Restoration Project, Review Period Ends: 03/16/2015, Contact: Lois Hill 208–935–4258. Revision to FR Notice Published 02/13/2015; Correction to Agency Contact Phone Number should be 208–935–4258.

EIS No. 20150034, Final EIS, USACE, OR, Double-crested Cormorant

Management Plan to Reduce Predation of Juvenile Salmonids in the Columbia River Estuary, Review Period Ends: 03/16/2015, Contact: Robert Winters 503–808–4738. Revision to FR Notice Published 02/13/2015; Correction to Document Status should be Final EIS.

Dated: February 17, 2015.

Dawn Roberts,

Management Analyst, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 2015–03524 Filed 2–19–15; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–9922–98–Region 6]

Underground Injection Control Program; Hazardous Waste Injection Restrictions; Petition for Exemption Reissuance—Class I Hazardous Waste Injection; Lucite International, Inc. Beaumont Site, Nederland, TX

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of a final decision on a no migration petition reissuance.

SUMMARY: Notice is hereby given that a reissuance of an exemption to the land disposal Restrictions, under the 1984 Hazardous and Solid Waste Amendments to the Resource Conservation and Recovery Act, has been granted to Lucite International, Inc. for two Class I hazardous injection wells located at their Beaumont site located in Nederland, TX. The company has adequately demonstrated to the satisfaction of the Environmental Protection Agency by the petition reissuance application and supporting documentation that, to a reasonable degree of certainty, there will be no migration of hazardous constituents from the injection zone for as long as the waste remains hazardous. This final decision allows the continued underground injection by Lucite, of the specific restricted hazardous wastes identified in this exemption reissuance, into Class I hazardous waste injection wells WDW–100 & 101 until December 31, 2030, unless EPA moves to terminate this exemption. Additional conditions included in this final decision may be reviewed by contacting the Region 6 Ground Water/UIC Section. A public notice was issued December 18, 2014. The public comment period closed on February 2, 2015. No comments were received. This decision constitutes final Agency action and there is no Administrative appeal. This decision may be reviewed/appealed in compliance with the Administrative Procedure Act.

DATES: This action is effective as of February 5, 2015.

ADDRESSES: Copies of the petition reissuance and all pertinent information relating thereto are on file at the following location: Environmental Protection Agency, Region 6, Water Quality Protection Division, Source Water Protection Branch (6WQ–S), 1445 Ross Avenue, Dallas, Texas 75202–2733.

FOR FURTHER INFORMATION CONTACT: Philip Dellinger, Chief Ground Water/UIC Section, EPA—Region 6, telephone (214) 665–8324.

Dated: February 5, 2015.

William K. Honker,

Director, Water Quality Protection Division.

[FR Doc. 2015–03463 Filed 2–19–15; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL DEPOSIT INSURANCE CORPORATION

Sunshine Act Meeting

Pursuant to the provisions of the ''Government in the Sunshine Act'' (5 U.S.C. 552b), notice is hereby given that at 10:03 a.m. on Tuesday, February 17, 2015, the Board of Directors of the Federal Deposit Insurance Corporation met in closed session to consider matters related to the Corporation's supervision, corporate, and resolution activities.

In calling the meeting, the Board determined, on motion of Vice Chairman Thomas M. Hoenig, seconded by Director Jeremiah O. Norton (Appointive), concurred in by Director Thomas J. Curry (Comptroller of the Currency), Director Richard Cordray (Director, Consumer Financial Protection Bureau), and Chairman Martin J. Gruenberg, that Corporation business required its consideration of the matters which were to be the subject of this meeting on less than seven days' notice to the public; that no earlier notice of the meeting was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting by authority of subsections (c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B) of the ''Government in the Sunshine Act'' (5 U.S.C. 552b(c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B).

The meeting was held by telephone.

Dated: February 17, 2015.

Federal Deposit Insurance Corporation.

Robert E. Feldman,

Executive Secretary.

[FR Doc. 2015–03605 Filed 2–18–15; 4:15 pm]

BILLING CODE 6714–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–D–0349]

Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft document entitled ''Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR part 1271'' dated February 2015. The draft guidance document is intended to provide manufacturers of human cells, tissues, and cellular and tissue-based products (HCT/Ps) for which no premarket submissions are required because they are not also regulated as drugs, devices, and/or biological products, with recommendations for complying with the requirements for investigating and reporting adverse reactions involving communicable disease in recipients of these HCT/Ps. The draft guidance, when finalized, is intended to supplement section XXII of FDA's guidance entitled ''Guidance for Industry: Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)'' dated December 2011 and supersede the guidance entitled ''Guidance for Industry: MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)'' dated November 2005.

DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by April 21, 2015.